UK markets closed
  • FTSE 100

    7,027.58
    +59.28 (+0.85%)
     
  • FTSE 250

    22,883.39
    +206.11 (+0.91%)
     
  • AIM

    1,232.54
    +4.45 (+0.36%)
     
  • GBP/EUR

    1.1675
    -0.0013 (-0.11%)
     
  • GBP/USD

    1.3754
    -0.0013 (-0.10%)
     
  • BTC-GBP

    24,681.15
    +1,083.52 (+4.59%)
     
  • CMC Crypto 200

    786.33
    -7.40 (-0.93%)
     
  • S&P 500

    4,411.79
    +44.31 (+1.01%)
     
  • DOW

    35,061.55
    +238.20 (+0.68%)
     
  • CRUDE OIL

    72.17
    +0.26 (+0.36%)
     
  • GOLD FUTURES

    1,802.10
    -3.30 (-0.18%)
     
  • NIKKEI 225

    27,548.00
    +159.80 (+0.58%)
     
  • HANG SENG

    27,321.98
    -401.86 (-1.45%)
     
  • DAX

    15,669.29
    +154.75 (+1.00%)
     
  • CAC 40

    6,568.82
    +87.23 (+1.35%)
     

Global Rare Hemophilia Factors Market to Reach $350.8 Million by 2027

·12-min read

Abstract: - Global Rare Hemophilia Factors Market to Reach $350. 8 Million by 2027. - Amid the COVID-19 crisis, the global market for Rare Hemophilia Factors estimated at US$252.

New York, June 21, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Rare Hemophilia Factors Industry" - https://www.reportlinker.com/p06032737/?utm_source=GNW
3 Million in the year 2020, is projected to reach a revised size of US$350.8 Million by 2027, growing at a CAGR of 4.8% over the analysis period 2020-2027. Fresh Frozen Plasma, one of the segments analyzed in the report, is projected to record a 4.7% CAGR and reach US$168.1 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Factor Concentrates segment is readjusted to a revised 5.6% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $74.3 Million, While China is Forecast to Grow at 4.6% CAGR
- The Rare Hemophilia Factors market in the U.S. is estimated at US$74.3 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$62.3 Million by the year 2027 trailing a CAGR of 4.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.4% and 4.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.
- Cryoprecipitate Segment to Record 4.2% CAGR
- In the global Cryoprecipitate segment, USA, Canada, Japan, China and Europe will drive the 4.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$34.6 Million in the year 2020 will reach a projected size of US$46.6 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$39.3 Million by the year 2027.

- Select Competitors (Total 40 Featured) -

  • Baxalta

  • Bayer healthcare

  • Bio Products Laboratory Ltd

  • Biogen

  • CSL Behring

  • Novo Nordisk

  • Pfizer, Inc.

  • Shire

  • Takeda Pharmaceutical Co. Ltd.




Read the full report: https://www.reportlinker.com/p06032737/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Rare Hemophilia
Factors by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR

Table 2: World Historic Review for Rare Hemophilia Factors by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 3: World 15-Year Perspective for Rare Hemophilia Factors
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Fresh Frozen
Plasma by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR

Table 5: World Historic Review for Fresh Frozen Plasma by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 6: World 15-Year Perspective for Fresh Frozen Plasma by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Factor
Concentrates by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR

Table 8: World Historic Review for Factor Concentrates by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 9: World 15-Year Perspective for Factor Concentrates by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Cryoprecipitate
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 11: World Historic Review for Cryoprecipitate by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 12: World 15-Year Perspective for Cryoprecipitate by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Other Treatments
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 14: World Historic Review for Other Treatments by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 15: World 15-Year Perspective for Other Treatments by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 16: USA Current & Future Analysis for Rare Hemophilia
Factors by Treatment - Fresh Frozen Plasma, Factor
Concentrates, Cryoprecipitate and Other Treatments -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 17: USA Historic Review for Rare Hemophilia Factors by
Treatment - Fresh Frozen Plasma, Factor Concentrates,
Cryoprecipitate and Other Treatments Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 18: USA 15-Year Perspective for Rare Hemophilia Factors
by Treatment - Percentage Breakdown of Value Sales for Fresh
Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other
Treatments for the Years 2012, 2020 & 2027

CANADA
Table 19: Canada Current & Future Analysis for Rare Hemophilia
Factors by Treatment - Fresh Frozen Plasma, Factor
Concentrates, Cryoprecipitate and Other Treatments -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 20: Canada Historic Review for Rare Hemophilia Factors by
Treatment - Fresh Frozen Plasma, Factor Concentrates,
Cryoprecipitate and Other Treatments Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 21: Canada 15-Year Perspective for Rare Hemophilia
Factors by Treatment - Percentage Breakdown of Value Sales for
Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and
Other Treatments for the Years 2012, 2020 & 2027

JAPAN
Table 22: Japan Current & Future Analysis for Rare Hemophilia
Factors by Treatment - Fresh Frozen Plasma, Factor
Concentrates, Cryoprecipitate and Other Treatments -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 23: Japan Historic Review for Rare Hemophilia Factors by
Treatment - Fresh Frozen Plasma, Factor Concentrates,
Cryoprecipitate and Other Treatments Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 24: Japan 15-Year Perspective for Rare Hemophilia Factors
by Treatment - Percentage Breakdown of Value Sales for Fresh
Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other
Treatments for the Years 2012, 2020 & 2027

CHINA
Table 25: China Current & Future Analysis for Rare Hemophilia
Factors by Treatment - Fresh Frozen Plasma, Factor
Concentrates, Cryoprecipitate and Other Treatments -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 26: China Historic Review for Rare Hemophilia Factors by
Treatment - Fresh Frozen Plasma, Factor Concentrates,
Cryoprecipitate and Other Treatments Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 27: China 15-Year Perspective for Rare Hemophilia Factors
by Treatment - Percentage Breakdown of Value Sales for Fresh
Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other
Treatments for the Years 2012, 2020 & 2027

EUROPE
Table 28: Europe Current & Future Analysis for Rare Hemophilia
Factors by Geographic Region - France, Germany, Italy, UK and
Rest of Europe Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 29: Europe Historic Review for Rare Hemophilia Factors by
Geographic Region - France, Germany, Italy, UK and Rest of
Europe Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 30: Europe 15-Year Perspective for Rare Hemophilia
Factors by Geographic Region - Percentage Breakdown of Value
Sales for France, Germany, Italy, UK and Rest of Europe Markets
for Years 2012, 2020 & 2027

Table 31: Europe Current & Future Analysis for Rare Hemophilia
Factors by Treatment - Fresh Frozen Plasma, Factor
Concentrates, Cryoprecipitate and Other Treatments -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 32: Europe Historic Review for Rare Hemophilia Factors by
Treatment - Fresh Frozen Plasma, Factor Concentrates,
Cryoprecipitate and Other Treatments Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 33: Europe 15-Year Perspective for Rare Hemophilia
Factors by Treatment - Percentage Breakdown of Value Sales for
Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and
Other Treatments for the Years 2012, 2020 & 2027

FRANCE
Table 34: France Current & Future Analysis for Rare Hemophilia
Factors by Treatment - Fresh Frozen Plasma, Factor
Concentrates, Cryoprecipitate and Other Treatments -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 35: France Historic Review for Rare Hemophilia Factors by
Treatment - Fresh Frozen Plasma, Factor Concentrates,
Cryoprecipitate and Other Treatments Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 36: France 15-Year Perspective for Rare Hemophilia
Factors by Treatment - Percentage Breakdown of Value Sales for
Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and
Other Treatments for the Years 2012, 2020 & 2027

GERMANY
Table 37: Germany Current & Future Analysis for Rare Hemophilia
Factors by Treatment - Fresh Frozen Plasma, Factor
Concentrates, Cryoprecipitate and Other Treatments -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 38: Germany Historic Review for Rare Hemophilia Factors
by Treatment - Fresh Frozen Plasma, Factor Concentrates,
Cryoprecipitate and Other Treatments Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 39: Germany 15-Year Perspective for Rare Hemophilia
Factors by Treatment - Percentage Breakdown of Value Sales for
Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and
Other Treatments for the Years 2012, 2020 & 2027

ITALY
Table 40: Italy Current & Future Analysis for Rare Hemophilia
Factors by Treatment - Fresh Frozen Plasma, Factor
Concentrates, Cryoprecipitate and Other Treatments -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 41: Italy Historic Review for Rare Hemophilia Factors by
Treatment - Fresh Frozen Plasma, Factor Concentrates,
Cryoprecipitate and Other Treatments Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 42: Italy 15-Year Perspective for Rare Hemophilia Factors
by Treatment - Percentage Breakdown of Value Sales for Fresh
Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other
Treatments for the Years 2012, 2020 & 2027

UNITED KINGDOM
Table 43: UK Current & Future Analysis for Rare Hemophilia
Factors by Treatment - Fresh Frozen Plasma, Factor
Concentrates, Cryoprecipitate and Other Treatments -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 44: UK Historic Review for Rare Hemophilia Factors by
Treatment - Fresh Frozen Plasma, Factor Concentrates,
Cryoprecipitate and Other Treatments Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 45: UK 15-Year Perspective for Rare Hemophilia Factors by
Treatment - Percentage Breakdown of Value Sales for Fresh
Frozen Plasma, Factor Concentrates, Cryoprecipitate and Other
Treatments for the Years 2012, 2020 & 2027

REST OF EUROPE
Table 46: Rest of Europe Current & Future Analysis for Rare
Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor
Concentrates, Cryoprecipitate and Other Treatments -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 47: Rest of Europe Historic Review for Rare Hemophilia
Factors by Treatment - Fresh Frozen Plasma, Factor
Concentrates, Cryoprecipitate and Other Treatments Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 48: Rest of Europe 15-Year Perspective for Rare
Hemophilia Factors by Treatment - Percentage Breakdown of Value
Sales for Fresh Frozen Plasma, Factor Concentrates,
Cryoprecipitate and Other Treatments for the Years 2012, 2020 &
2027

ASIA-PACIFIC
Table 49: Asia-Pacific Current & Future Analysis for Rare
Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor
Concentrates, Cryoprecipitate and Other Treatments -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 50: Asia-Pacific Historic Review for Rare Hemophilia
Factors by Treatment - Fresh Frozen Plasma, Factor
Concentrates, Cryoprecipitate and Other Treatments Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 51: Asia-Pacific 15-Year Perspective for Rare Hemophilia
Factors by Treatment - Percentage Breakdown of Value Sales for
Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and
Other Treatments for the Years 2012, 2020 & 2027

REST OF WORLD
Table 52: Rest of World Current & Future Analysis for Rare
Hemophilia Factors by Treatment - Fresh Frozen Plasma, Factor
Concentrates, Cryoprecipitate and Other Treatments -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 53: Rest of World Historic Review for Rare Hemophilia
Factors by Treatment - Fresh Frozen Plasma, Factor
Concentrates, Cryoprecipitate and Other Treatments Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 54: Rest of World 15-Year Perspective for Rare Hemophilia
Factors by Treatment - Percentage Breakdown of Value Sales for
Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate and
Other Treatments for the Years 2012, 2020 & 2027

IV. COMPETITION
Total Companies Profiled: 40
Read the full report: https://www.reportlinker.com/p06032737/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting